Financial Comparison: Tevogen Bio (NASDAQ:TVGN) & Genfit (NASDAQ:GNFT)

Genfit (NASDAQ:GNFT) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

Volatility & Risk

Genfit has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Tevogen Bio has a beta of -1.36, suggesting that its stock price is 236% less volatile than the S&P 500.

Profitability

This table compares Genfit and Tevogen Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genfit	N/A	N/A	N/A
Tevogen Bio	N/A	-396.07%	749.97%

Institutional and Insider Ownership

2.2% of Genfit shares are owned by institutional investors. 4.2% of Genfit shares are owned by company insiders. Comparatively, 56.6% of Tevogen Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for Genfit and Tevogen Bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genfit	0	0	1	0	3.00
Tevogen Bio	0	0	1	0	3.00

Genfit presently has a consensus target price of $13.00, indicating a potential upside of 250.40%. Tevogen Bio has a consensus target price of $4.20, indicating a potential upside of 300.00%. Given Tevogen Bio’s higher probable upside, analysts plainly believe Tevogen Bio is more favorable than Genfit.

Earnings and Valuation

This table compares Genfit and Tevogen Bio”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genfit	$76.06 million	2.44	-$31.27 million	N/A	N/A
Tevogen Bio	N/A	N/A	-$70,000.00	N/A	N/A

Tevogen Bio has lower revenue, but higher earnings than Genfit.

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

About Tevogen Bio

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.